US2011281798A1PendingUtilityA1

Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs

61
Assignee: KOLTERMAN ORVILLE GPriority: Jan 14, 1999Filed: Mar 10, 2011Published: Nov 17, 2011
Est. expiryJan 14, 2019(expired)· nominal 20-yr term from priority
Inventors:Orville G. KoltermanAndrew A. YoungJames J. L'Italien
A61K 38/26A61K 38/16A61P 5/48A61K 38/00C07K 14/605A61K 47/60A61P 3/10C07K 14/57563
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method of lowering plasma glucagon in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:45, 46, or 48 to lower plasma glucagon. 
     
     
         16 . The method of  claim 15 , wherein the human has necrolytic migratory erythema. 
     
     
         17 . The method of  claim 15 , wherein the human has glucagonoma. 
     
     
         18 . The method of  claim 15 , wherein the human has type 2 diabetes. 
     
     
         19 . The method of  claim 15 , comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:45. 
     
     
         20 . The method of  claim 19 , wherein Xaa 1  is 4-imidazopropionyl in SEQ ID NO:45. 
     
     
         21 . The method of  claim 19 , Xaa 2  is Gly in SEQ ID NO:45. 
     
     
         22 . The method of  claim 19 , wherein Xaa 14  is Leu, pentylglycine, or Met in SEQ ID NO:45. 
     
     
         23 . The method of  claim 19 , wherein Xaa 25  is Trp or Phe in SEQ ID NO:45. 
     
     
         24 . The method of  claim 15 , comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:46. 
     
     
         25 . The method of  claim 24 , wherein Xaa 1  is His or 4-imidazopropionyl in SEQ ID NO:46. 
     
     
         26 . The method of  claim 24 , Xaa 2  is Gly in SEQ ID NO:46. 
     
     
         27 . The method of  claim 24 , wherein Xaa 14  is Leu, pentylglycine, or Met in SEQ ID NO:46. 
     
     
         28 . The method of  claim 24 , wherein Xaa 25  is Trp or Phe in SEQ ID NO:46. 
     
     
         29 . The method of  claim 15 , comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:48. 
     
     
         30 . The method of  claim 29 , wherein Xaa 1  is His or 4-imidazopropionyl in SEQ ID NO:48. 
     
     
         32 . The method of  claim 29 , wherein Xaa 14  is Leu, pentylglycine, or Met in SEQ ID NO:48. 
     
     
         33 . The method of  claim 29 , wherein Xaa 25  is Trp or Phe in SEQ ID NO:48. 
     
     
         34 . A method of suppressing glucagon secretion in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:45, 46, or 48 to suppress glucagon secretion.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.